Breast tumor tissue inflammation but not lobular involution is associated with survival among breast cancer patients in the Multiethnic Cohort

e13002 Background: Despite improvement in survival in breast cancer patients from advanced therapies, rates of chemotherapy-induced cardiotoxicity manifesting as a decline in left ventricular ejection fraction (LVEF) have offset some of these benefits in patients receiving anthracycline-based chemotherapy followed by trastuzumab. Results suggesting clinical biomarkers predict cardiotoxicity are inconsistent. Recently, expression of angiotensin II type 1 receptor (ATR1) and endothelin 1 (ET1) has shown to play a role in breast tumor growth. We sought to evaluate whether the presence of ATR1 and ET1 in breast cancer tissue using immunohistochemistry (IHC) and qRT-PCR can predict chemotherapy-induced cardiotoxicity. Methods: We hypothesized that elevated expression of ATR1 and ET1 in tumor tissue is associated with chemotherapy-induced cardiotoxicity (LVEF < 50%) compared to tissue from controls. Preliminarily, 34 paraffin-embedded breast tissue specimens from women with breast cancer treated with anthracycline-based chemotherapy and trastuzumab were retrieved for analysis. IHC and qRT-PCR for expression of ATR1 and ET1 was performed on all specimens. Results: We found that ET1 expression was significantly increased in patients with an LVEF < 50%. In addition, we noted the lower the LVEF, the higher the ET1 expression (p = 0.03). We also found patients with a change in LVEF of greater than 10% had more ET1 expression compared to those without a change in LVEF (p = 0.05). We did not find a significant relationship between ATR1 and LVEF. Conclusions: Increased ET1 expression in breast tumor tissue may predict cardiotoxicity. Our findings may aid in future research using novel biomarkers to predict breast cancer patients at risk for developing chemotherapy-induced cardiotoxicity. In addition, targeted therapies to these biomarkers may potentially help prevent the development of cardiotoxicity.

Download Full-text

Cytomegalovirus, Macrophages and Breast Cancer

The Open Virology Journal ◽

10.2174/1874357901711010015 ◽

2017 ◽

Vol 11 (1) ◽

pp. 15-27 ◽

Cited By ~ 4

Author(s):

S. Pasquereau ◽

F. Al Moussawi ◽

W. Karam ◽

M. Diab Assaf ◽

A. Kumar ◽

...

Keyword(s):

Breast Cancer ◽

Epithelial Cells ◽

Human Cytomegalovirus ◽

Breast Tumor ◽

Poor Prognosis ◽

Tumor Tissue ◽

Tumor Associated Macrophages ◽

Potential Implication ◽

Breast Tumor Tissue

The human cytomegalovirus (HCMV) is a betaherpesvirus that is highly host specific, infects among others epithelial cells and macrophages, and has been recently mentioned as having oncomodulatory properties. HCMV is detected in the breast tumor tissue where macrophages, especially tumor associated macrophages, are associated with a poor prognosis. In this review, we will discuss the potential implication of HCMV in breast cancer with emphasis on the role played by macrophages.

Download Full-text

The Value of a Second Opinion for Breast Cancer Patients Referred to a National Cancer Institute (NCI)-Designated Cancer Center with a Multidisciplinary Breast Tumor Board

Annals of Surgical Oncology ◽

10.1245/s10434-018-6599-y ◽

2018 ◽

Vol 25 (10) ◽

pp. 2953-2957 ◽

Cited By ~ 10

Author(s):

Denise Garcia ◽

Laura S. Spruill ◽

Abid Irshad ◽

Jennifer Wood ◽

Denise Kepecs ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

National Cancer Institute ◽

Breast Tumor ◽

Second Opinion ◽

Tumor Board ◽

Cancer Center ◽

Breast Cancer Patients

Download Full-text

The Impact of Mental Illness on Uptake of Genetic Counseling for Hereditary Breast Cancer and Ovarian Cancer in a Multiethnic Cohort of Breast Cancer Patients

The Breast Journal ◽

10.1111/tbj.12791 ◽

2017 ◽

Vol 23 (5) ◽

pp. 519-524 ◽

Cited By ~ 2

Author(s):

Marra G. Ackerman ◽

Peter A. Shapiro ◽

Austin Coe ◽

Meghna S. Trivedi ◽

Katherine D. Crew

Keyword(s):

Breast Cancer ◽

Ovarian Cancer ◽

Mental Illness ◽

Genetic Counseling ◽

Cancer Patients ◽

Hereditary Breast Cancer ◽

Breast Cancer Patients ◽

Multiethnic Cohort ◽

The Impact

Download Full-text

Micropallet Technology for Investigating Tumor Cellular Profiles and Analysis of Rare Cell Subsets

ASME 2008 3rd Frontiers in Biomedical Devices Conference ◽

10.1115/biomed2008-38058 ◽

2008 ◽

Author(s):

Nicholas M. Gunn ◽

Mark Bachman ◽

Edward L. Nelson ◽

G.-P. Li

Keyword(s):

Breast Cancer ◽

United States ◽

Cancer Patients ◽

Invasive Breast Cancer ◽

Breast Tumor ◽

The United States ◽

Therapeutic Strategies ◽

Cellular Heterogeneity ◽

Breast Cancer Patients ◽

Critical Limits

Rationally designed, individualized therapeutic strategies have long been a desired objective for breast cancer patients and clinicians as an estimated 178,480 new cases of invasive breast cancer will be diagnosed among women in the United States this year and over 40,000 women are expected to die from the disease. [1] The increasing appreciation of breast tumor cellular heterogeneity raises fundamental questions as to the relative contributions of cellular subsets to the biologic behavior of an individual patient’s tumor. [2] As such, it has become increasingly clear that in many cases, an individualized strategy for the treatment of breast cancer would be of great benefit, and that the ability to isolate relevant cellular subsets from the main tumor population is one of the critical limits to accomplishing this goal.

Download Full-text